Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Buy Of Ranbaxy By Daiichi Sankyo Faces Regulatory Delay

This article was originally published in PharmAsia News

Executive Summary

Japan's Daiichi Sankyo says its plan to acquire India's Ranbaxy Laboratories will be delayed because it still has not received regulatory authority for the offer. The Japanese drug maker had planned to make an open offer for 20 percent of Ranbaxy shares Aug. 8, but said it could not meet that date because Indian regulators had not yet approved the move. The company had set an Aug. 27 deadline for a response to the offer. A new schedule is to be announced after ICICI Securities clears the way, Daiichi said. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts